Abstract
Nuclear factor-κB (NF-κB) is a transcription factor that is activated in response to various inflammatory stimuli such as cytokines, growth factors, hormones, mitogens, carcinogens, chemotherapeutic agents, viral products, eukaryotic parasites, endotoxin, fatty acids, metals, radiation, hypoxia, and psychological, physical, oxidative, and chemical stresses. In addition, constitutively active NF-κB is frequently encountered in a wide variety of tumors, including breast, ovarian, colon, pancreatic, thyroid, prostate, lung, head and neck, bladder, and skin cancers; B-cell lymphoma; Hodgkins disease; T-cell lymphoma; adult T-cell leukemia; acute lymphoblastic leukemia; multiple myeloma; chronic lymphocytic leukemia; and acute myelogenous leukemia. Furthermore, NF-κB activation has been shown to regulate the expression of over 400 genes involved in cellular transformation, proliferation, inflammation, viral replication, antiapoptosis, angiogenesis, invasion and metastasis, oxidative stress, and osteoclastogenesis. Therefore, because of the critical role NF- κB plays in the pathogenesis of cancer, specific inhibitors of this factor are being sought. Agents that prevent cancer or inflammation have been found to suppress NF-κB activation. Although IκBκ kinase is the major kinase, over 30 different protein kinases have been linked to the activation of NF-κB by different stimuli. The development of a drug that can specifically suppress NF-κB activation requires a full understanding of the mechanism by which NF-κB is activated in response to these various stimuli.
Keywords: NF-kB, IKK, antitumor, TNF, inflammation
Current Signal Transduction Therapy
Title: Nuclear Factor-κB: A Holy Grail in Cancer Prevention and Therapy
Volume: 1 Issue: 1
Author(s): Bharat B. Aggarwal, Gautam Sethi, Asha Nair and Haruyo Ichikawa
Affiliation:
Keywords: NF-kB, IKK, antitumor, TNF, inflammation
Abstract: Nuclear factor-κB (NF-κB) is a transcription factor that is activated in response to various inflammatory stimuli such as cytokines, growth factors, hormones, mitogens, carcinogens, chemotherapeutic agents, viral products, eukaryotic parasites, endotoxin, fatty acids, metals, radiation, hypoxia, and psychological, physical, oxidative, and chemical stresses. In addition, constitutively active NF-κB is frequently encountered in a wide variety of tumors, including breast, ovarian, colon, pancreatic, thyroid, prostate, lung, head and neck, bladder, and skin cancers; B-cell lymphoma; Hodgkins disease; T-cell lymphoma; adult T-cell leukemia; acute lymphoblastic leukemia; multiple myeloma; chronic lymphocytic leukemia; and acute myelogenous leukemia. Furthermore, NF-κB activation has been shown to regulate the expression of over 400 genes involved in cellular transformation, proliferation, inflammation, viral replication, antiapoptosis, angiogenesis, invasion and metastasis, oxidative stress, and osteoclastogenesis. Therefore, because of the critical role NF- κB plays in the pathogenesis of cancer, specific inhibitors of this factor are being sought. Agents that prevent cancer or inflammation have been found to suppress NF-κB activation. Although IκBκ kinase is the major kinase, over 30 different protein kinases have been linked to the activation of NF-κB by different stimuli. The development of a drug that can specifically suppress NF-κB activation requires a full understanding of the mechanism by which NF-κB is activated in response to these various stimuli.
Export Options
About this article
Cite this article as:
Aggarwal B. Bharat, Sethi Gautam, Nair Asha and Ichikawa Haruyo, Nuclear Factor-κB: A Holy Grail in Cancer Prevention and Therapy, Current Signal Transduction Therapy 2006; 1 (1) . https://dx.doi.org/10.2174/157436206775269235
DOI https://dx.doi.org/10.2174/157436206775269235 |
Print ISSN 1574-3624 |
Publisher Name Bentham Science Publisher |
Online ISSN 2212-389X |
![Wayfinder Image](/images/wayfinder.jpg)
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Stem Cell Dynamics and Heterogeneity: Implications for Epidermal Regeneration and Skin Cancer
Current Medicinal Chemistry Ipilimumab and Vemurafenib: Two Different Routes for Targeting Melanoma
Current Cancer Drug Targets Polypeptide Toxins from Animal Venoms
Recent Patents on DNA & Gene Sequences Hydrogel-clay Nanocomposites as Carriers for Controlled Release
Current Medicinal Chemistry Editorial [Hot Topic: Nanotechnology Enables Superior Medical Therapies (Guest Editors: Marianna Foldvari & Mahmoud Elsabahy)]
Current Drug Delivery Double Layered Hydroxides as Potential Anti-Cancer Drug Delivery Agents
Mini-Reviews in Medicinal Chemistry Naturally Occurring Peptides from Rana temporaria: Antimicrobial Properties and More
Current Topics in Medicinal Chemistry 5-Fluorouracil Derivatives Induce Differentiation Mediated by Tubulin and HLA Class I Modulation
Medicinal Chemistry Innovative Therapeutic Strategies for Restoring Lymphocyte Functions in Septic Patients
Inflammation & Allergy - Drug Targets (Discontinued) Pluripotency-Regulating Networks Provide Basis for Reprogramming
Current Molecular Medicine Cardiovascular Complications of HIV Infection and Treatment
Cardiovascular & Hematological Agents in Medicinal Chemistry Targeting ATP7A to Increase the Sensitivity of Neuroblastoma Cells to Retinoid Therapy
Current Cancer Drug Targets Altered Expression of microRNAs in Serum Extracellular Vesicles in Rats with Severe Burns during Shock Stage
Current Molecular Medicine The Functions of Histone Modification Enzymes in Cancer
Current Protein & Peptide Science FbD Supported Development and In Vitro Evaluation of Carbomer based Resveratrol Loaded Topical Antipsoriatic Nanoemulgel for its Targeted Skin Delivery
Pharmaceutical Nanotechnology Anticancer Agents Derived from Natural Products
Mini-Reviews in Medicinal Chemistry Network of WNT and Other Regulatory Signaling Cascades in Pluripotent Stem Cells and Cancer Stem Cells
Current Pharmaceutical Biotechnology Imaging with Raman Spectroscopy
Current Pharmaceutical Biotechnology Inhibition of Cdc42-Interacting Protein 4 (CIP4) Impairs Osteosarcoma Tumor Progression
Current Cancer Drug Targets Hijacking the Hedgehog Pathway in Cancer Therapy
Anti-Cancer Agents in Medicinal Chemistry